Weight loss drug investors "understandably unhappy": "So far, Qsymia hasn't rocketed into the stratosphere"

http://www.fiercepharma.com/story/faced-flat-sales-vivus-offers-free-trial-qsymia-weight-loss-drug/2012-11-26

Faced with flat sales, Vivus offers free trial on Qsymia weight loss drug

November 26, 2012 | By Tracy Staton

"Vivus ($VVUS) has been under the microscope since it launched its new weight-loss drug Qsymia. It's the first of several obesity fighters set to hit the market, and all eyes are on its performance, both as an indicator of the company's fortunes and of its rivals' prospects.

So far, Qsymia hasn't rocketed into the stratosphere.

.....................

If Vivus can goose those script numbers upward, then that might calm some restless investors, who have been understandably unhappy with the stock's recent performance. Earlier this month, one big shareholder called for a sale of the company to a bigger drugmaker that could better market the drug."






Read more: Faced with flat sales, Vivus offers free trial on Qsymia weight loss drug - FiercePharma http://www.fiercepharma.com/story/faced-flat-sales-vivus-offers-free-trial-qsymia-weight-loss-drug/2012-11-26#ixzz2DLszD500
Subscribe: http://www.fiercepharma.com/signup?sourceform=Viral-Tynt-FiercePharma-FiercePharma